Orano Med

hope in the fight against cancer

Orano Med, Orano’s medical subsidiary, is combining biotechnology and nuclear energy to develop targeted cancer treatments using the unique properties of lead-212 (212Pb).

Its work is fueling the hope that the international medical community will move toward less toxic, more effective treatments for patients with limited treatment options.

  • 62employees
  • 12developments in progress
  • 2units working on the production of lead-212 in France and the United States
  • 2laboratory projects for the production and distribution of radiopharmaceuticals in the United States and France (ATLabs)

The properties of lead-212

Lead-212 is a very rare radioactive isotope that comes from thorium. Orano’s expertise in cutting-edge nuclear technologies has made it possible to develop a unique process that contributes to the extraction and purification of lead-212. This rare metal is used in the development of several promising targeted cancer treatments referred to as “Targeted Alpha Therapy”.

56 pages

www.publispeak.com